{"id":"lamotrigine-aripiprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Akathisia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lamotrigine reduces the release of excitatory neurotransmitters (glutamate and aspartate) by blocking voltage-gated sodium channels, providing mood-stabilizing effects. Aripiprazole functions as a partial agonist at dopamine D2 and D3 receptors, reducing dopaminergic hyperactivity in psychosis while maintaining baseline dopamine signaling. The combination targets both glutamatergic and dopaminergic pathways to address symptoms of bipolar disorder and related conditions.","oneSentence":"Lamotrigine stabilizes neuronal membranes by blocking sodium channels, while aripiprazole acts as a dopamine D2/D3 receptor partial agonist, together modulating neurotransmission to treat mood and psychotic disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:51:35.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bipolar I disorder maintenance treatment"},{"name":"Bipolar depression"}]},"trialDetails":[{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT00531518","phase":"NA","title":"Early Detection and Intervention for the Prevention of Psychosis","status":"COMPLETED","sponsor":"MaineHealth","startDate":"2007-10","conditions":"Schizophrenia, Bipolar Disorder, Depression","enrollment":292},{"nctId":"NCT00926835","phase":"PHASE4","title":"Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients","status":"TERMINATED","sponsor":"Ministry of Health & Welfare, Korea","startDate":"2009-05","conditions":"Major Depressive Disorder","enrollment":692},{"nctId":"NCT01584765","phase":"","title":"Rechallenge, Potential Drug Induced Liver Injury (Kaiser)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-02","conditions":"Drug-induced Liver Injury","enrollment":1},{"nctId":"NCT00277212","phase":"PHASE4","title":"A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2005-12","conditions":"Bipolar Disorder","enrollment":1169},{"nctId":"NCT00321516","phase":"PHASE1","title":"Drug-drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2006-07","conditions":"Bipolar Disorder","enrollment":20},{"nctId":"NCT01000402","phase":"PHASE4","title":"Juvenile Bipolar Disorder Outpatient Program","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2008-02","conditions":"Bipolar Disorder, Attention Deficit Disorder With Hyperactivity","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Abilify","BMS-337039"],"phase":"marketed","status":"active","brandName":"Lamotrigine + Aripiprazole","genericName":"Lamotrigine + Aripiprazole","companyName":"Otsuka Pharmaceutical Development & Commercialization, Inc.","companyId":"otsuka-pharmaceutical-development-commercialization-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lamotrigine stabilizes neuronal membranes by blocking sodium channels, while aripiprazole acts as a dopamine D2/D3 receptor partial agonist, together modulating neurotransmission to treat mood and psychotic disorders. Used for Bipolar I disorder maintenance treatment, Bipolar depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}